Drug intelligence / Profile preview

REGEND002

Development stage: Preclinical
Lead developer: Regend Therapeutics
Modality: Gene Addition/Replacement → Gene Therapies, Gene Silencing → Gene Therapies, Gene Editing → Gene Therapies, Stem Cell Therapies → Cell Therapies
Administration: Inhalation, Intrabronchial

Overview

REGEND002 is an autologous, genetically modified lung precursor stem cell therapy developed by Regend Therapeutics for the treatment of bronchiectasis. The therapy utilizes P63+ lung progenitor cells (LPCs) to promote the regeneration and repair of damaged lung tissue. By transplanting these progenitor cells, the treatment aims to rebuild the bronchial structure and alleviate chronic inflammation and fibrosis associated with bronchiectasis. It represents a regenerative medicine approach within Regend's respiratory disease pipeline.

Other names: P63+ lung progenitor cellsP63+ LPCs

Beyond the preview

Go deeper on REGEND002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on REGEND002.

Explore the full profile